Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients

European Journal of Cancer

Volumn 38, Issue 14, 2002, Pages 1824-1831

  Efficace, F ^a   Bottomley, A ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Brain cancer; Quality of life; Randomised controlled trials; Systematic review

Indexed keywords

ANTINEOPLASTIC AGENT;

BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; HUMAN; MEDICAL RECORD; MEDLINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0036711431     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00173-9     Document Type: Article

References (34)

1. Stupp R., Gander M., Leyvraz S., Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2:2001;552-560.
2. Surawicz T.S., Davis F., Freels S., Laws E.R. Jr., Menck H.R. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol. 40:1998;151-160.
3. Levin V.A., Kyristis A.P. Gliomas, medulloblastoma, and CNS germ cell tumors. Cavalli F., Hansen H.H., Kaye S.B. Textbook of Medical Oncology. 2000;493-520 Martin Dunitz, London.
4. Kleihues P., Burger P.C., Scheithauer B.W. Histological Typing of Tumours of the Central Nervous System. 1993;Springer-Verlag, Berlin.
5. Blomgren H. Brain tumors. Acta Oncol. 35:1996;16-21.
6. Dinnes J., Cave C., Huang S., Major K., Milne R. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma. a rapid and systematic review Health Technol Assess. 5:2001;1-73.
7. Osoba D., Brada M., Prados M.D., Yung W.K. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-oncology. 2:2000;221-228.
8. Souhami R., Tobias J. Cancer and Its Management. 1998;Blackwell Science, London.
9. Laperriere N.J., Leung P.M., McKenzie S.et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys. 41:1998;1005-1011.
10. Kiebert G.M., Curran D., Aaronson N.K.et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult. results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group Eur J Cancer. 34:1998;1902-1909.
11. Pickles T., Goodman G.B., Rheaume D.E.et al. Pion radiation for high grade astrocytoma. results of a randomized study Int J Radiat Oncol Biol Phys. 37:1997;491-497.
12. Kochii M., Kitamura I., Goto T.et al. Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma. J Neurooncol. 49:2000;63-70.
13. Sanders C., Egger M., Donovan J., Tallon D., Frankel S. Reporting on quality of life in randomised controlled trials. bibliographic study BMJ. 317:1998;1191-1194.
14. Slevin M.L., Plant H., Lynch D., Drinkwater J., Gregory W.M. Who should measure quality of life the doctor or the patient? Br J Cancer. 57:1988;109-112.
15. Fayers P., Machin D. Quality of Life. Assessment, Analysis and Interpretation. 2000;John Wiley and Sons, Chichester.
16. Staquet M., Berzon R., Osoba D., Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res. 5:1996;496-502.
17. Bottomley A., Thomas R., Van Steen K., Flechtner H., Djulbegovic B. Human recombinant erythropoietin and quality of life. a wonder drug or something to wonder about? Lancet Oncol. 3:2002;145-153.
18. Yung W.K., Albright R.E., Olson J.et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 83:2000;588-593.
19. Bampoe J., Laperriere N., Pintilie M., Glen J., Micallef J., Bernstein M. Quality of life in patients with glioblastoma multiforme participating in a randomized study of brachytherapy as a boost treatment. J Neurosurg. 93:2000;917-926.
20. Trojanowski T., Peszynski J., Turowski K.et al. Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. J Neurosurg. 70:1989;18-23.
21. Karim A.B., Maat B., Hatlevoll R.et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma. European Organization for Research and Treatment of Cancer (EORTC) Study 22844 Int J Radiat Oncol Biol Phys. 36:1996;549-556.
22. Schumacher M., Olschewski M., Schulgen G. Assessment of quality of life in clinical trials. Stat Med. 10:1991;1915-1930.
23. Bergner M., Bobbitt R.A., Carter W.B., Gilson B.S. The Sickness Impact Profile. development and final revision of a health status measure Med Care. 19:1981;787-805.
24. Osoba D., Aaronson N.K., Muller M.et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 5:1996;139-150.
25. Osoba D., Brada M., Yung W.K., Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 18:2000;1481-1491.
26. Lenartz D., Stoffel B., Menzel J., Beuth J. Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res. 16:1996;3799-3802.
27. Vecht C.J., Hovestadt A., Verbiest H.B., van Vliet J.J., van Putten W.L. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors. a randomized study of doses of 4, 8, and 16 mg per day Neurology. 44:1994;675-680.
28. Sandberg-Wollheim M., Malmstrom P., Stromblad L.G.et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer. 68:1991;22-29.
29. Murray K.J., Nelson D.F., Scott C.et al. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02. Int J Radiat Oncol Biol Phys. 31:1995;453-459.
30. Cianfriglia F., Pompili A., Riccio A., Grassi A. CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme. Cancer. 45:1980;1289-1299.
31. Titzer M.L., Fisch M., Kristeller J.L.et al. Clinicians' assessment of quality of life (qol) in outpatients with advanced cancer. how accurate is our prediction? A Hoosier Oncology Group Study Proc Am Soc Clin Oncol. 20:2001;1532.
32. Sprangers M.A., Aaronson N.K. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. a review J Clin Epidemiol. 45:1992;743-760.
33. Stephens R.J., Hopwood P., Girling D.J.et al. Randomized trials with quality of life endpoints. are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res. 6:1997;225-236.
34. da Silva F.C., Fossa S.D., Aaronson N.K.et al. The quality of life of patients with newly diagnosed M1 prostate cancer. experience with EORTC clinical trial 30853 Eur J Cancer. 32:1996;72-77.